TruthArchive.ai - Related Video Feed

There are concerns about the long-term side effects of modifying DNA and RNA to enable the production of antibodies. The potential for causing mutations or other risks in the future is uncertain.

The speaker asks the regulator if they would request sponsors to conduct intensive analysis to anticipate any immunogenicity issues when reviewing a dossier with extensive optimization. The regulator responds that they understand the burden and do not require specific assays. They ask for protein characterization and perform an in silico analysis. If they identify any red flags, they may request further analysis. They typically ask for standard characterization and do not add extra detail. However, if adverse events related to codon optimized proteins arise, they may increase scrutiny. The conversation ends.

"Packaged DNA fragments have been found en masse as vaccine contaminants." "Once they reach the nucleus, short DNA sequences have an increased propensity to insert into chromosomal DNA." "The possible consequences are unending." "Disruption of the exquisitely tuned network that controls cell division and differentiation can lead to cancer and to developmental defects." "Mutations in sperm and fertilized egg cells could render altered traits inheritable." "Cost effective procedures to reliably separate mass produced RNA from plasmids do not exist." "Contamination of RNA vaccines with plasmid DNA must therefore be expected to be the rule and not the exception." "Whoever propagates RNA vaccines as being safe and effective, whoever claims that nothing can happen to your genome, is either incredibly ignorant or endlessly evil."

Moderna holds a patent for using RNA in vaccines, acknowledging that RNA is superior to DNA due to concerns about DNA-related problems like insertional immunogenesis and genotoxicity. The FDA claims to be unaware of any issues, but Moderna's own patent raises the same concerns about DNA. It appears that DNA is present in the RNA preparation as a contaminant, as it is used in the process of making RNA. Recent findings by scientists revealed large numbers of DNA fragments in the RNA preparation, including sequences that are not normally allowed in human use, such as an antibiotic resistance gene and sequences from simian virus 40. These DNA fragments can potentially lead to DNA damage, birth defects, and cancer.

Integrating foreign genes into chromosomes can lead to cancer and other health issues, permanently altering genetics and affecting future generations. This is a call to recognize the dangers posed by RNA vaccines being introduced globally by organizations like the WHO, CDC, and FDA. The initial vaccines have already shown harmful effects due to the introduction of foreign genes into the body. The production of mRNA does not ensure that these genes, often derived from bacteria, won't enter human cells. As a result, individuals receiving these vaccines may experience genetic alterations, and any genetically altered cell is at risk.

Speaker 0: I read the sequence and it's high-resolution. Speaker 1: It may seem low at first, but it's understandable. Speaker 0: This is written in a loop. Speaker 1: This is the genetic sequence of the spike protein. The issue is that the model RNA has a sequence that surprised me. We need to design it a bit. It contains part of the sequence SB4T, which is necessary for gene expression. The problem is that it is found in a virus that has negative effects. Also, there is another problem with this sequence. The DNA that has been transferred so far becomes more susceptible to mutation. It's a problematic point. Speaker 1: So, this SB4T sequence is also included in the promoter of this SB method, which allows it to migrate to the nucleus. Speaker 0: This is quite famous. Speaker 1: Yes, it is. The issue is that it has no relation to the process of synthesizing the messenger RNA. Speaker 0: Why did they keep the promoter sequence in the SB4T that has nothing to do with the camera's perspective in the messenger RNA synthesis process?

The speaker asks the regulator if they would request sponsors to conduct intensive analysis to anticipate any immunogenicity issues when reviewing dossiers with extensive optimization. The regulator responds that they understand the burden and do not require specific assays, but they do ask for protein characterization and perform an in silico analysis. If they identify any red flags, they may request further analysis. They generally ask for standard characterization and may increase scrutiny if adverse events specific to optimized proteins arise. The conversation ends with a thank you.

Moderna holds a patent for using RNA in vaccines, acknowledging that RNA is better than DNA due to concerns about DNA-related problems like insertional immunogenesis and genotoxicity. The FDA claims to be unaware of these concerns, but Moderna's own patent highlights them. The presence of DNA in the vaccines is considered a contaminant, as it is used in the process of making RNA. Recent findings by scientists in the US and Canada revealed large amounts of DNA fragments in the RNA preparation, including sequences not allowed for human use, such as an antibiotic resistance gene and sequences from simian virus 40. These DNA fragments pose risks of DNA damage, including birth defects and cancer.

Using more c and g in biotechnology translates proteins quicker, evading the immune system. However, altering the folding structure by increasing GC content in Pfizer's and Moderna's drugs poses risks. Computer models show significant differences in folding between the drugs and the natural virus, potentially leading to prion disease concerns. These modifications make the drugs more hazardous than the original virus.

The spike protein may inhibit tumor suppressor genes like MHS 3p53 and BRCA2, potentially leading to cancer. The mRNA vaccine contains a base that allows the spike protein to be produced for longer, possibly further inhibiting tumor suppressor genes. Concerns are raised about the long-term effects of these vaccines, with a call for them to be banned for general use and reserved for gene therapy in advanced cancer cases.

We compared gene expression profiles across several groups: a healthy control group pre COVID, individuals described as mRNA injured, a group with cancer, and a few individuals who had neurological and cardiovascular adverse events. The analysis showed that in the mRNA injured group, thousands of gene expressions become dysfunctional in several key cellular pathways. Specifically, dysfunction was noted in mitochondrial function, immune function, and protein production. The changes included the production of abnormal proteins as a result of these altered gene expressions. In addition, the analysis reported that cancer surveillance genes were literally turned off in the mRNA injured group. The genes mentioned as turned off include p53, KRAS, and BRCA. This observation is presented as part of the overall pattern of molecular disruption associated with the mRNA injury state. Overall, the findings are described as indicating that flooding the body with synthetic messenger RNA unleashes biochemical havoc. The speaker emphasizes that this biochemical havoc has severe consequences, as evidenced by the observed widespread gene expression dysfunction and the suppression of critical cancer surveillance genes, alongside the production of abnormal proteins and impairments in mitochondrial, immune, and protein production pathways.

Many labs, including Medicinal Genomics, found DNA contamination in Pfizer and Moderna mRNA vaccines. Regulators like the FDA and EMA admitted to this, but downplayed its significance. The SP 40 sequences omitted by Pfizer are crucial. DNA contamination can cause insertional mutagenesis, as stated in Moderna's patents. Regulatory agencies were deceived and failed to properly address the issue. This poses a serious risk that cannot be ignored.

The regulator is asked if they would require sponsors to conduct intensive analysis to anticipate immunogenicity issues when reviewing dossiers. The regulator responds that they do not ask for such analysis, but rather request sponsors to characterize their proteins and perform in silico analysis. They acknowledge the necessity of codon optimization and only intervene if there are red flags or adverse events related to codon optimized proteins. They emphasize the importance of standard characterization and may increase scrutiny if adverse events arise.

Researchers conducted a study to investigate the production of incorrect proteins in mice and humans after vaccination. They found that one-third of the tested individuals produced antibodies against these mistranslated proteins, indicating their presence. The study highlighted the potential risks of mRNA technology, as multiple mistranslations could lead to the production of various incorrect proteins. These proteins may not be useful and could trigger an immune response. The researchers emphasized the need for further research to understand the impact on the immune system and prevent any potential harm.

The introduction of foreign genes into human chromosomes can lead to immediate cancer and inflammation, and these changes can be passed on to future generations. This is a serious warning about the dangers posed by RNA vaccines being introduced globally by organizations like the WHO, CDC, and FDA. The first vaccines have already been released, and they are causing significant harm by introducing foreign genes into the body. The production of mRNA does not ensure that these bacterial genes will not enter human cells, resulting in genetic alterations. Any cell that undergoes such genetic changes is at risk.

The speakers describe a study in which gene expression profiles are compared across several groups to assess the impact of mRNA injury. The comparison set includes a healthy control group that was observed before the COVID-19 era, individuals classified as mRNA injured, a subset of three individuals with cancer, and a smaller number of participants who exhibited neurological and cardiovascular adverse events. The central finding reported is that, in the mRNA-injured group, thousands of gene expressions become dysfunctional. The dysfunction spans several critical cellular and biological processes, notably mitochondrial function, immune function, and protein production. The speakers indicate that these alterations include the production of abnormal proteins as a consequence of the disrupted gene expression patterns. In addition to widespread dysfunction in metabolic and cellular pathways, the speakers note that genes involved in cancer surveillance are turned off in the mRNA-injured group. Specific genes named are p53, KRAS, and BRCA, with their expression or regulatory activity described as being suppressed or deactivated. The implication conveyed is that the disruption of cancer surveillance mechanisms accompanies the broader profile of gene expression changes observed in response to the mRNA injury. The overall conclusion presented by the speakers is that flooding the body with synthetic messenger RNA is associated with unleashing biochemical havoc, which they characterize as having severe consequences. The framing suggests a causal or strongly associative link between exposure to synthetic mRNA and the observed downstream effects on gene expression, including mitochondrial and immune dysfunction, abnormal protein production, and the suppression of key cancer-related surveillance genes. The narrative emphasizes the magnitude of the molecular disturbances, noting that thousands of gene expressions become dysfunctional and that critical safeguards against cancer may be compromised in the mRNA-injured group.

The DNA sequence in gene therapy plasmids contains the SV40 promoter and enhancer region, an SV40 origin of replication, and an SV40 poly A signal. The SV40 enhancers are nuclear targeting sequences, ensuring the DNA enters the cell nucleus, especially during cell division when the nuclear envelope dissolves. Claims that it doesn't reach the nucleus are misleading. This plasmid was sourced from Pfizer's gene therapy department. The SV40 promoter and enhancer bind to the p53 gene, a tumor suppressor, which is concerning given that the spike protein also inhibits p53 expression. Literature indicates this sequence is a hypermutability element, inducing mutations in nearby DNA, suggesting potential tumorigenic activity. These findings contradict claims that this DNA has no function.

The mRNA platform is effective but has a flaw: it can cause autoimmune disorders by producing foreign proteins in cells. The challenge is to target only specific cells and avoid damage to vital organs. The pandemic allowed the emergency use authorization of mRNA vaccines, bypassing safety measures. However, a large portion of the population has already accepted this technology. To address the issue, a solution could be to replace the spike protein with a different protein that doesn't have flaws. But if the problem lies in any foreign protein transcribed by cells, the immune system may still target vital organs.

Alden and colleagues found that Pfizer's genetic code can be integrated into the human genome within an hour in a cancerous cell line. This suggests that Pfizer and Moderna's genetic material might become a permanent part of human DNA. There is no study confirming or denying this possibility. The concern is that if eggs or sperm incorporate this genetic code, it could be passed on to future generations. This lack of research is seen as reckless and worrisome.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Speaker 0 cautions about the long-term side effects of directly modifying a person’s DNA and RNA to encode antibodies. They raise concerns that such genetic or molecular modifications could lead to unforeseen consequences over time, including potential mutations or other risks that might arise downstream as a result of encoding these antibodies.

Current optimization, often considered harmless, can actually have negative effects. Synonymous mutations, which don't change the translated amino acid, have been linked to diseases. The reasons behind this association are often unknown, but factors like translation rate and RNA structure have been implicated. Since many synonymous mutations have been associated with disease, it is possible that codon optimization, which involves multiple substitutions, could also have an impact. This has been extensively reviewed.

The discussion reports a comparative analysis of gene expression profiles among four groups: a healthy control group pre-COVID, individuals who were injured by mRNA, and subgroups including three individuals with cancer and a few with neurological and cardiovascular adverse events. The study found that in the mRNA injured group, thousands of gene expressions become dysfunctional, affecting mitochondrial function, immune function, and protein production, leading to the creation of abnormal proteins. It also notes that cancer surveillance genes are literally turned off, specifically mentioning p53 and KRAS, as well as BRCA. The overall claim is that flooding the body with synthetic messenger RNA unleashes biochemical havoc, with severe consequences.

Researchers conducted experiments on mice and humans to investigate the production of antibodies against mistranslated proteins caused by frame shifts in mRNA technology. They found that one-third of the tested individuals had antibodies against these incorrect proteins, indicating their production. The study emphasized the need to address this issue as repeated use of mRNA technology in higher doses could result in the production of numerous incorrect proteins. Additionally, the immune system may attack these proteins, potentially leading to autoimmune responses. The researchers called for further investigation into the impact of these mistranslated proteins on the immune system.

RNA sequencing of the Moderna vaccine's three prime ends suggests a possible mechanism for RNA persistence: in vivo re-adenylation. The data indicates plasmid DNA contamination despite efforts to reduce it. The data also reveals contamination from other mRNA vaccines in Moderna's pipeline. The speaker suggests that with widespread DNA sequencing capabilities, tolerating incorrect RNA sizes in vaccines is irresponsible. Sequencing before approval would have allowed for a better understanding of low RNA scores before global administration.